%0 Journal Article
%T 原发性肠道非霍奇金淋巴瘤穿孔的临床预后分析
%A 勾红峰
%A 陈心传
%J 华西医学
%P 1960-1963
%D 2010
%X 【】　目的　对原发性肠道非霍奇金淋巴瘤穿孔患者的临床及病理特征、诊治、预后进行探讨。　方法　回顾性分析1999年1月-2008年12月诊治的17例原发性肠道非霍奇金淋巴瘤穿孔患者的临床资料。　结果　B细胞型9例，T细胞型8例。17例原发肠道非霍奇金淋巴瘤穿孔患者的穿孔部位大肠7例，小肠7例，回盲部3例。所有患者均行手术治疗。除2例穿孔前行化疗的患者以外，其余患者术前均未明确诊断。有14例获得随访结果，6例术后3个月内死亡，术后接受化疗者7例，1、2、3年生存率分别为41.2%、23.6%、11.7%，仅1例生存期超过5年。　结论　原发性肠道非霍奇金淋巴瘤穿孔术前诊断困难，预后极差。？【Abstract】　Objective　Toanalyzetheclinicalfeatures,diagnosis,therapyandprognosisofprimaryintestinalnon-hodgkin′slymphomaperforation.　Methods　Theclinicaldataof17patientswiththeprimaryintestinalnon-Hodgkin′slymphomaperforationfromJanuary1999toDecember2008wereretrospectivelyanalyzed.　Results　NinepatientshadintestinalB-celllymphoma,andeighthadintestinalT-celllymphoma.Thesitesofperforationwereasfollowscolonandrectumin7(41.2%),ileumandjejunumin7(41.2%),andileocecaljunctionin3(17.6%).Allpatientshadundergonetheoperations.ThediseasewasnotdiagnosedbeforetheoperationinallofthepatientsexceptfortheTwopatientshadahistoryofsystemicchemotherapybeforeperforation.Atotalof14patientswerefollowedup,inwhomsixdiedwithinthreemonthsaftertheoperation;thesurvivalrate1,2,and3yearsaftertheoperationwas41.2%,23.6%,and11.7%,respectivelyinsevenpatientswhohadundergonethesystemicchemotherapybeforetheoperation;onepatientslivedmorethan5years.　Conclusion　Thediagnosisofprimarycolonicmalignantlymphomaperforationisdifficult;theprognosisismiserable.
%K 肠肿瘤
%K 淋巴瘤
%K 穿孔
%K 预后
%U http://www.hxyxqk.com.cn/oa/DArticle.aspx?type=view&id=201011008